This study aimed to look at the treatment response of four cycles of three-weekly administrations of AC followed by paclitaxel weekly or every three weeks in a neoadjuvant setting in HER2-negative, stage III breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.